Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001)

被引：1
|
作者：
Liu, Jing
Wu, Junwei
Zhu, Liangjun
Yan, Jun
Mao, Yong
Tang, Xinyu
Zhu, Lingjun
Jiang, Hong
Wei, Xiaowei
Shangguan, Chengfang
Xi, Wenqi
Shi, Yan
Shi, Min
Zhou, Chenfei
Yang, Hui
Zhang, Jun
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[2] Jiansu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[3] Shanghai Univ Med & Hlth Sci, Jiading Cental Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Jiannan Univ, Affiliated Hosp, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[5] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[6] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[7] Tongji Univ, Tongji Hosp, Dept Oncol, Shanghai, Peoples R China
[8] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS229
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001)
    Zhou, Chenfei
    Wu, Junwei
    Yan, Jun
    Wang, Chun
    Mao, Yong
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Wang, Chunbing
    Qin, Zhiquan
    Han, Zhengxiang
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multicenter phase II trial (ALTER-G-001)
    Wu, J.
    Zhang, J.
    Zhou, C.
    Yan, J.
    Zhu, L.
    Jiang, J.
    Wang, C.
    Chen, J.
    Han, Z.
    Wang, C.
    Yong, M.
    Tang, X.
    Qin, Z.
    Wei, X.
    Shangguan, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S902 - S902
  • [3] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
    Zhou, C.
    Zhang, J.
    Wu, J.
    Jiang, J.
    Zhu, L.
    Yan, J.
    Wang, C.
    Mao, Y.
    Tang, X.
    Chen, J.
    Wang, C.
    Qin, Z.
    Han, Z.
    Wei, X.
    Shangguan, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S50 - S51
  • [4] Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
    Wu, Jun-Wei
    Zhou, Chen-Fei
    Han, Zheng-Xiang
    Zhang, Huan
    Yan, Jun
    Chen, Jun
    Wang, Chun-Bin
    Qin, Zhi-Quan
    Mao, Yong
    Tang, Xin-Yu
    Zhu, Liang-Jun
    Wei, Xiao-Wei
    Cui, Dong-Hai
    Yang, Xiu-Li
    Shi, Min
    Zhao, Li-Qin
    Jiang, Jin-Ling
    Zhu, Wei-You
    Wang, Hong-Mei
    Wang, Chun
    Zhu, Ling-Jun
    Zhang, Jun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [5] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C
    Wu, J.
    Zhou, C.
    Yan, J.
    Han, Z.
    Wang, C.
    Qin, Z.
    Jiang, J.
    Wang, C.
    Tang, X.
    Zhu, L.
    Chen, J.
    Mao, Y.
    Wei, X.
    Shangguan, C.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1533 - S1533
  • [6] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
    Wu, J.
    Zhu, L.
    Zhou, C.
    Shi, M.
    Chen, J.
    Zhao, L.
    Han, Z.
    Wang, C.
    Jiang, J.
    Yan, J.
    Wei, X.
    Mao, Y.
    Yang, X.
    Qin, Z.
    Tang, X.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1510 - S1511
  • [7] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbin
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    CANCER RESEARCH, 2024, 84 (07)
  • [8] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Zhu, Liangjun
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 653 - 653
  • [10] Anlotinib plus chemotherapy as first-line (1L) treatment in gastrointestinal cancer patients with unresectable liver metastases
    Wu, J.
    Zhu, L.
    Zhou, C.
    Shi, M.
    Chen, J.
    Zhao, L.
    Han, Z.
    Wang, C.
    Mao, Y.
    Zhu, L.
    Wei, X.
    Jiang, J.
    Yan, J.
    Wang, C.
    Qin, Z.
    Cui, D.
    Yang, X.
    Tang, X.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1443 - S1443
12345